An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs Acalabrutinib (Primary) ; Rituximab
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions
- Sponsors Acerta Pharma
- 18 Jun 2019 Planned number of patients changed from 126 to 80.
- 18 Jun 2019 Planned End Date changed from 1 Oct 2022 to 1 May 2023.
- 18 Jun 2019 Planned primary completion date changed from 1 Oct 2022 to 1 May 2023.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History